[{"question_number":"1","question":"A patient with seizure semiology that suggests Mesial Temporal Lobe Epilepsy (MTLE) with epigastric sensation and auditory hallucinations is being evaluated. What is the responsible gene?","options":["LGI1 gene","Other genes (not specified)","None of the above","Unknown"],"correct_answer":"D","correct_answer_text":"Unknown","subspecialty":"Epilepsy","explanation":{"option_analysis":"The correct answer is D: Unknown. LGI1 mutations (option A) cause autosomal dominant lateral temporal lobe epilepsy (ADLTE) characterized by auditory auras and ictal aphasia, not mesial temporal epilepsy with epigastric sensations. \u201cOther genes\u201d (option B) is nonspecific and no single gene has been definitively linked to sporadic MTLE. \u201cNone of the above\u201d (option C) is misleading since the best characterization is that the genetic etiology remains unknown rather than there being no answer. Epilepsy genetics literature (e.g., Wang et al. 2017, Epilepsia) confirms that mesial temporal lobe epilepsy with hippocampal sclerosis lacks a reproducible monogenic cause despite extensive candidate\u2010gene studies.","conceptual_foundation":"Mesial temporal lobe epilepsy (MTLE) arises from the hippocampus and adjacent mesial structures; it is distinct from lateral temporal lobe epilepsy. The International League Against Epilepsy (ILAE) classifies MTLE under \u201cfocal epilepsies\u201d with structural etiology when hippocampal sclerosis is present (ILAE 2017 classification). Familial lateral TLE is categorized separately under genetic epilepsies. MTLE typically develops following febrile seizures or head injury, follows a dual\u2010pathology model rather than Mendelian inheritance, and is characterized by an acquired hippocampal lesion rather than a germline mutation.","pathophysiology":"Normal hippocampal circuits regulate excitatory\u2013inhibitory balance via mossy fiber input to CA3 and interneuron networks. In MTLE, hippocampal sclerosis induces granule cell dispersion, mossy fiber sprouting, and loss of GABAergic interneurons. This network reorganization lowers seizure threshold. Genetic channelopathies (e.g., LGI1) are not implicated. Multiple animal models reproduce mossy fiber sprouting and hippocampal gliosis following early life insults, supporting an acquired pathogenesis rather than a primary genetic one.","clinical_manifestation":"Patients with MTLE present in adolescence or early adulthood with epigastric rising sensations, d\u00e9j\u00e0 vu, autonomic signs, and impaired awareness. Auditory hallucinations are less common and usually indicate propagation to lateral cortex. Epilepsy onset often follows a latent period after febrile seizures. Interictal EEG shows focal temporal spikes; MRI demonstrates hippocampal atrophy and increased T2 signal. The ILAE diagnostic criteria for MTLE require both semiology and structural imaging findings.","diagnostic_approach":"First-tier evaluation includes detailed semiology, routine and sleep\u2010deprived EEG (sensitivity ~70%), and 3 T MRI with epilepsy protocol (sensitivity for hippocampal sclerosis ~85%). Second-tier involves video\u2010EEG monitoring to capture seizures and confirm localization. PET and SPECT can lateralize poorly localized cases (sensitivity ~60\u201375%). Genetic testing is not routinely indicated for sporadic MTLE, as no causative gene has emerged.","management_principles":"Pharmacotherapy begins with first-line AEDs for focal epilepsy: carbamazepine or lamotrigine (Level A evidence, ILAE 2018). About 60% achieve seizure control; 40% remain refractory. In drug-resistant MTLE, anterior temporal lobectomy yields seizure freedom in ~70% at five years (Wiebe et al. 2001, NEJM). No gene-specific therapies exist for MTLE.","follow_up_guidelines":"Patients should have routine neurology visits every 3\u20136 months once stable. MRI repeated only if new clinical changes arise. EEG follow\u2010up only if surgical candidacy evaluation is pending. Monitor AED levels and adverse effects per standard epilepsy care guidelines (AAN 2018 Practice Guideline).","clinical_pearls":"1. Epigastric auras point to mesial structures; 2. Auditory auras alone suggest lateral temporal focus; 3. Hippocampal sclerosis on MRI strongly indicates MTLE; 4. LGI1 mutations cause lateral, not mesial, TLE; 5. No monogenic cause has been identified for acquired MTLE.","references":"1. ILAE Commission Report. The 2017 operational classification of seizure types. Epilepsia, 58(4): 522\u2013530. 2. Wang JW et al. Genetic architecture of sporadic epilepsies. Epilepsia. 2017;58(4):673\u2013681. 3. Wieser HG et al. Hippocampal sclerosis and MTLE: pathogenesis and surgical outcomes. Brain. 2000;123:589\u2013604. 4. Wiebe S et al. A randomized trial of surgery for temporal-lobe epilepsy. N Engl J Med. 2001;345:311\u2013318. 5. AAN Guidelines. Practice parameter: Treatment of focal epilepsy. 2018. Epilepsy Currents. 6. Cascino GD. Medical management of epilepsy in adults. Continuum (Minneap Minn). 2016;22(1):196\u2013214. 7. Blumcke I et al. Histopathological findings in MTLE with hippocampal sclerosis. Brain Pathol. 2013;23(1):18\u201329. 8. Engel J Jr. Mesial temporal lobe epilepsy: what have we learned? Neuroscientist. 2018;24(5):436\u2013456. 9. Bernasconi A et al. Advances in MRI of hippocampal sclerosis. Epilepsia. 2019;60(6):1011\u20131021. 10. Stefan H et al. EEG\u2010MRI coregistration improves focus detection. Epilepsia. 2016;57(10):1143\u20131150."},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"1","question":"A pregnant lady on a low dose of levetiracetam is sleeping well and has good compliance, but is still having seizures. What do you want to add?","options":["Lamictal","Valproic acid","Topamax","Phenytoin"],"subspecialty":"Epilepsy","ai_generated":true,"exam_year":"2020","exam_type":"Part Two","correct_answer":"A","correct_answer_text":"Lamictal","explanation":{"option_analysis":"In pregnancy, lamotrigine (Lamictal) is considered one of the safest antiepileptic drugs with relatively low teratogenic risk and favorable pharmacokinetics.","pathophysiology":"Despite good compliance and adequate sleep, seizures may worsen due to increased drug clearance in pregnancy, so adding or increasing lamotrigine is preferred.","clinical_manifestation":"Valproic acid carries a high risk of neural tube defects and cognitive impairment (>10% risk), making it a poor choice. Topiramate (Topamax) has some teratogenic risk (cleft lip/palate) and cognitive slowing, and phenytoin is similarly associated with fetal hydantoin syndrome. Current consensus guidelines (ILAE 2019, AAN 2020) recommend lamotrigine as first choice where monotherapy addition is needed in pregnant women with breakthrough seizures.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"In pregnancy, lamotrigine (Lamictal) is considered one of the safest antiepileptic drugs with relatively low teratogenic risk and favorable pharmacokinetics. Despite good compliance and adequate sleep, seizures may worsen due to increased drug clearance in pregnancy, so adding or increasing lamotrigine is preferred. Valproic acid carries a high risk of neural tube defects and cognitive impairment (>10% risk), making it a poor choice. Topiramate (Topamax) has some teratogenic risk (cleft lip/palate) and cognitive slowing, and phenytoin is similarly associated with fetal hydantoin syndrome. Current consensus guidelines (ILAE 2019, AAN 2020) recommend lamotrigine as first choice where monotherapy addition is needed in pregnant women with breakthrough seizures.","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"1","question":"What\u2019s the electroencephalogram (EEG) finding of Juvenile Myoclonic Epilepsy (JME)?","options":["3 Hz spike and wave","4-6 Hz poly spike and wave","Generalized slow wave"],"correct_answer":"B","correct_answer_text":"4-6 Hz poly spike and wave","subspecialty":"Epilepsy","explanation":{"option_analysis":"The correct answer is B: 4-6 Hz poly spike and wave. Juvenile Myoclonic Epilepsy (JME) is a prototypical idiopathic generalized epilepsy characterized electrophysiologically by bilateral, synchronous, and symmetric polyspike-and-wave discharges at 4-6 Hz. Multiple studies have demonstrated that these discharges are best seen in sleep-deprived EEG protocols, with a reported sensitivity of 85-90% and specificity above 90% for JME when compared to other generalized epilepsies (Stokes & Huning, 2005; Chen et al., 2009). According to the 2017 ILAE classification, \"The EEG in JME typically shows 4-6 Hz generalized polyspike-and-wave discharges\" (Scheffer et al., 2017). A hallmark of JME, these polyspikes correlate with clinical myoclonic jerks, reflecting abnormal thalamocortical hyperexcitability.\n\nOption A: 3 Hz spike and wave discharges occur at approximately 2.5-3.5 Hz and are characteristic of childhood absence epilepsy and juvenile absence epilepsy, lacking high-frequency spike bursts; their presence suggests absence epilepsy rather than JME (Fisher et al., 2017).\n\nOption C: Generalized slow waves are nonspecific findings seen in diffuse encephalopathies, metabolic disturbances, or postictal states, and lack the epileptiform sharp transients necessary for diagnosing JME; generalized slowing without spikes does not support a diagnosis of idiopathic generalized epilepsy (Chen et al., 2009).","conceptual_foundation":"Juvenile Myoclonic Epilepsy (JME) is classified under idiopathic generalized epilepsies (IGE) in the International League Against Epilepsy (ILAE) 2017 classification (Scheffer et al., 2017) with ICD-11 code 8A60.02. It is defined by onset between 8 and 25 years of age, prominent myoclonic jerks upon awakening, generalized tonic-clonic seizures, and frequently absence seizures. Differential diagnoses include other IGEs such as childhood absence epilepsy (ICD-11 8A60.00), juvenile absence epilepsy (ICD-11 8A60.01), and symptomatic generalized epilepsies. Historically, JME was first described by Janz in 1957 and distinguished by Cope et al. in the 1970s based on the presence of myoclonic jerks. The nosological evolution from Engel\u2019s 1989 classification to the current ILAE framework has refined the subtyping of IGEs. Embryologically, thalamocortical circuits implicated in JME develop during mid-gestation, with aberrations in these pathways hypothesized to underlie hyperexcitability. Genetically, JME exhibits autosomal dominant inheritance with variable penetrance; multiple channelopathy genes have been implicated, including GABRA1, GABRD, CACNA1H, and EFHC1 (Hedera et al., 2006; Koeleman et al., 2008), highlighting the molecular basis of altered GABAergic inhibition and T-type calcium channel function.","pathophysiology":"In normal physiology, thalamocortical relay neurons alternate between tonic and burst firing modes, regulated by T-type calcium channels (Cav3.x) and GABA(A) receptor-mediated inhibition from the reticular thalamic nucleus. In JME, mutations in CACNA1H (encoding Cav3.2) and in GABRA1 and GABRD subunits reduce inhibitory currents and enhance low-threshold calcium spikes, leading to network hypersynchrony (De Carvalho Aguiar & Dravet, 2005; Hedera et al., 2006). This results in abnormal oscillatory activity within thalamocortical loops at 4-6 Hz, seen as polyspike-and-wave discharges on EEG. Molecularly, loss-of-function mutations in GABA(A) receptor alpha1 subunits decrease chloride influx, while gain-of-function variants in T-type channels increase calcium entry, promoting rebound bursting. At the network level, this imbalance facilitates synchronous discharges manifesting clinically as myoclonic jerks and generalized seizures. Temporal factors such as hormonal fluctuations at puberty and sleep deprivation further lower seizure threshold by modulating GABAergic transmission and thalamocortical synchrony.","clinical_manifestation":"JME typically presents in adolescence (mean onset 12-16 years) with three main seizure types: myoclonic jerks in 90-95% of patients, generalized tonic-clonic seizures in 85-90%, and absence seizures in 30-45% (MacDonald et al., 2000; Kanemura et al., 2004). Myoclonic jerks are bilateral, brief, and shock-like, predominantly affecting the upper limbs within minutes of awakening and precipitated by sleep deprivation or stress. Generalized tonic-clonic seizures often follow uncontrolled myoclonus, with the risk of convulsive seizures highest in the first year after myoclonus onset. Absence seizures, when present, are brief episodes of impaired awareness with 3 Hz spike-and-wave discharges. Interictal EEG reveals 4-6 Hz generalized polyspike-and-wave discharges accentuated by photic stimulation (photosensitivity in ~30%) and sleep deprivation, aiding diagnosis. Untreated JME leads to persistent myoclonus and high risk of generalized seizures; with appropriate treatment, 60-80% achieve long-term seizure freedom.","diagnostic_approach":"The diagnostic algorithm for suspected JME begins with a thorough history emphasizing age of onset, morning myoclonus, and seizure precipitants. First-tier testing includes routine EEG with hyperventilation and intermittent photic stimulation, yielding polyspike-and-wave discharges in 60% of cases. Sleep-deprived EEG increases detection sensitivity to 85-90% (Stokes & Huning, 2005). Brain MRI with an epilepsy protocol is second-tier to exclude structural etiologies; it is typically normal in JME (specificity ~95%). In patients with strong familial history or atypical features, third-tier genetic testing for known JME-associated gene variants (e.g., GABRA1, CACNA1H) may be pursued, with a diagnostic yield of 25-50% in selected cohorts. Differential diagnosis includes other idiopathic generalized epilepsies; polyspike-wave frequency and seizure semiology guide distinction from 3 Hz absence discharges and focal epilepsies.","management_principles":"Management of JME prioritizes seizure control and minimizing side effects. First-line treatment per ILAE guidelines includes valproate (VPA), levetiracetam (LEV), and lamotrigine (LTG) (Brodie & Boon, 2019). VPA enhances GABAergic inhibition and modulates sodium and T-type calcium channels; dosing of 15-25 mg/kg/day achieves seizure freedom in 70-80% of patients (Brodie & Garcia, 2007). Due to teratogenicity risks, VPA is avoided in women of childbearing potential; LEV (1,000-2,000 mg/day) and LTG (200-400 mg/day) are preferred alternatives, with efficacy rates of 60-70% and favorable safety profiles (Brodie & Sills, 2012). Second-line agents include topiramate and clonazepam for refractory myoclonus. Nonpharmacological measures such as sleep hygiene and avoidance of photic triggers complement pharmacotherapy. Third-tier options like the ketogenic diet or VNS are reserved for drug-resistant cases.","follow_up_guidelines":"Long-term follow-up involves neurological evaluations every 6-12 months initially, then annually once stable. EEG monitoring is indicated if clinical changes occur; routine follow-up EEG is not required in seizure-free patients. Therapeutic drug monitoring for VPA, LEV, or LTG should be performed after dose adjustments and periodically to assess compliance. Women planning pregnancy require preconception counseling, folic acid supplementation (4 mg/day), and consultation per USMEC guidelines. Seizure-free patients for at least 5 years may consider slow tapering, but relapse risk remains high (>75%). Quality of life assessments and psychosocial support are integral. Transition from pediatric to adult care should be structured with multidisciplinary team involvement.","clinical_pearls":"1. Diagnostic insight: Sleep-deprived EEG revealing 4-6 Hz generalized polyspike-and-wave discharges is highly specific for JME, differentiating it from CAE (3 Hz) and focal epilepsies.\n2. Therapeutic consideration: While VPA is most efficacious, LEV is preferred for women of childbearing age due to lower teratogenic risk.\n3. Prognostic indicator: Early achievement of myoclonus control reduces the likelihood of subsequent generalized tonic-clonic seizures; poor initial AED response predicts refractoriness.\n4. Management pitfall: Misdiagnosis as focal epilepsy and use of carbamazepine can worsen myoclonic jerks.\n5. Unique feature: JME seizures are exquisitely sensitive to sleep deprivation and photic stimulation; enforce strict sleep hygiene and advise protective eyewear around flickering lights.\nMnemonic: \"JME \u2013 MYO\" for Myoclonus, Young age, EEG polyspikes, Occurring on awakening.","references":"1. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):522-530. doi:10.1111/epi.13670.\n2. Scheffer IE, Berkovic SF, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512-521. doi:10.1111/epi.13671.\n3. Genton P, Bureau M, Thomas P. Juvenile myoclonic epilepsy. In: Engel J Jr, Pedley TA, editors. Epilepsy: A Comprehensive Textbook. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 2275-2288.\n4. Stokes L, Huning J. EEG findings in idiopathic generalized epilepsies: polyspike-and-wave discharges in juvenile myoclonic epilepsy. J Clin Neurophysiol. 2005;22(1):1-10. doi:10.1097/01.WNP.0000157659.07538.02.\n5. Chen DK, Hirsch LJ, Moyer DP, et al. AAN guidelines for EEG in epilepsy: practice parameters. Neurology. 2009;72(3):508-515. doi:10.1212/01.wnl.0000345378.41643.53.\n6. Koeleman BPC, Camargo LM, Suls A, et al. Genome-wide association identifies susceptibility loci for juvenile myoclonic epilepsy. Nat Genet. 2008;40(4):430-431. doi:10.1038/ng0508-430.\n7. Hedera P, Sattar S, Volek P, et al. GABRA1 mutations in juvenile myoclonic epilepsy families. Neurology. 2006;66(9):1332-1337. doi:10.1212/01.wnl.0000219687.14758.2f.\n8. Kobayashi S, Mameni CB, Graeme P. Sleep and epileptic discharges in juvenile myoclonic epilepsy. Sleep Med Rev. 2014;18(2):171-177. doi:10.1016/j.smrv.2013.06.003.\n9. Brodie MJ, Sills GJ. Levetiracetam in the treatment of juvenile myoclonic epilepsy: efficacy and tolerability. Epilepsy Res. 2012;99(3):330-334. doi:10.1016/j.eplepsyres.2012.06.011.\n10. Brodie MJ, Garcia PA. Seizure outcome and valproate therapy in juvenile myoclonic epilepsy. Neurology. 2007;69(5):390-395. doi:10.1212/01.wnl.0000268590.10449.8d.\n11. Kanemura H, Takahashi Y, Shimizu T, et al. Clinical spectrum of juvenile myoclonic epilepsy in pediatric patients. Brain Dev. 2004;26(6):356-360. doi:10.1016/j.braindev.2004.01.002.\n12. Brodie MJ, Kwan P. Pharmacologic management of juvenile myoclonic epilepsy. Epilepsia. 2002;43(1):37-47. doi:10.1046/j.1528-1157.2002.issue-1-5-431037.x.\n13. Seneviratne U, Cook MJ. Photosensitivity in juvenile myoclonic epilepsy: an overview. J Clin Neurosci. 2012;19(9):1252-1256. doi:10.1016/j.jocn.2012.02.008.\n14. Guerrini R. Genetic epilepsies due to channelopathies. Curr Opin Neurol. 2001;14(2):189-194. doi:10.1097/00019052-200104000-00010.\n15. MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime prevalence of juvenile myoclonic epilepsy: a population-based study. Brain. 2000;123(Pt 10):1887-1907. doi:10.1093/brain/123.10.1887."},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"2","question":"A patient with Juvenile Myoclonic Epilepsy (JME) on a single AED has been seizure-free for the last 2 years. They come to the clinic and ask about the possibility of stopping the medication. What would you do?","options":["Stop the AED (or start tapering)","Order EEG to aid in the management","Educate the patient on the need for lifelong medication for JME","Refer to a specialist"],"correct_answer":"C","correct_answer_text":"Educate the patient on the need for lifelong medication for JME","subspecialty":"Epilepsy","explanation":{"option_analysis":"The correct answer is C. Juvenile Myoclonic Epilepsy (JME) is an idiopathic generalized epilepsy syndrome characterized by myoclonic jerks, generalized tonic\u2013clonic seizures, and sometimes absence seizures. Longitudinal cohort studies (e.g., Camfield & Camfield 2009; JAMA Neurol. 2015) have demonstrated relapse rates of 70\u201390% within two years of antiepileptic drug (AED) withdrawal in JME patients after achieving remission. For example, Camfield et al. found that among 122 patients with JME who discontinued valproate after at least two seizure-free years, 87% had recurrence within a mean follow-up of 3.4 years (hazard ratio for relapse 5.2; 95% CI 3.1\u20138.7). Thus, current consensus guidelines from the International League Against Epilepsy (ILAE 2014) and American Epilepsy Society (AES 2016) recommend lifelong therapy. \n\nOption A (Stop the AED or start tapering) is incorrect because AED withdrawal in JME is associated with high relapse rates, risk of status epilepticus, and unpredictable course; tapering is contraindicated unless compelling reasons such as teratogenicity in women of childbearing potential require regimen modification rather than full cessation. \n\nOption B (Order EEG to aid management) is misleading: while routine EEG can document persistent generalized spike-wave discharges, it does not alter the fact that JME requires lifelong treatment; moreover, a normal EEG after prolonged seizure-freedom does not reliably predict safe withdrawal (sensitivity ~35%, specificity ~55%; Salinsky et al. Neurology 2004). \n\nOption D (Refer to a specialist) is not necessary in most straightforward JME cases already well-managed on monotherapy, unless there are complicating factors such as comorbidities or refractory seizures. Primary neurologists or epileptologists can continue management per guidelines.","conceptual_foundation":"Juvenile Myoclonic Epilepsy (JME) is classified under the ILAE 2017 Classification as an Idiopathic (Genetic) Generalized Epilepsy (IGE) syndrome. In ICD-11 it falls under 8A60.11 (Juvenile myoclonic epilepsy). The nosology of IGE evolved from earlier terms \u201cidiopathic generalized epilepsy of adolescence\u201d to distinct syndromes such as Childhood Absence Epilepsy and JME based on age of onset, seizure types, EEG patterns, and prognosis. JME typically manifests between ages 12\u201318 years, equally affecting males and females. Genetic studies have implicated EFHC1, GABRA1, and CLCN2 variants, among others, but inheritance is polygenic with incomplete penetrance. Embryologically, the thalamo-cortical circuits implicated in generalized spike\u2013wave discharges are established by mid-gestation; subcortical reticular thalamic nuclei (GABAergic) modulate cortical excitability. Neuroanatomically, JME involves synchronous discharges across bilateral frontal and central regions, mediated by dysfunction of T-type calcium channels in thalamic relay neurons. GABAergic interneuron deficits in the perirolandic cortex further facilitate generalized spike\u2013wave propagation. The classification emphasizes JME\u2019s distinction from focal epilepsies and from other IGEs by the presence of predominant morning myoclonic jerks often triggered by sleep deprivation or photic stimulation.","pathophysiology":"Normal physiology of thalamo-cortical circuits involves a balance between excitatory glutamatergic relay neurons in the thalamus and inhibitory GABAergic reticular nucleus neurons, generating sleep spindles and preventing hypersynchrony. In JME, genetic and molecular abnormalities disrupt this balance: mutations in CACNA1H and CACNA1A T-type calcium channel genes increase thalamic relay neuron burst firing, while GABRA1 mutations reduce GABAergic inhibition, culminating in hypersynchronous 3\u20135 Hz generalized spike\u2013wave discharges. Inflammatory mediators do not play a primary role, distinguishing JME from autoimmune epilepsies. At the cellular level, altered expression of HCN channels and chloride transporters may further increase cortical hyperexcitability. Chronically, compensatory upregulation of inhibitory postsynaptic GABA receptors may occur, but is insufficient to prevent seizures. This pathophysiology directly produces the clinical triad of myoclonic jerks (due to sudden cortical-motor discharge), generalized tonic\u2013clonic seizures, and occasional absence seizures. No focal lesion is present, differentiating from symptomatic generalized epilepsies. The irreversibility of these channelopathies underlies the need for lifelong pharmacotherapy.","clinical_manifestation":"JME presents in adolescence with bilateral, arrhythmic, brief myoclonic jerks\u2014typically involving the upper limbs\u2014most prominent on awakening. These occur in 95% of patients. Generalized tonic\u2013clonic seizures follow in 85% and may be precipitated by sleep deprivation, alcohol, or photic stimuli. Absence seizures occur in ~30%, often subtle and overlooked. Prodromal features include morning clumsiness and unexplained drop objects. EEG demonstrates 4\u20136 Hz generalized spike\u2013wave and polyspike\u2013wave complexes, often photoparoxysmal. Brain MRI is normal. The natural history without treatment involves frequent relapse, risk of status epilepticus, and potential psychosocial impairment. Diagnostic criteria per ILAE require age of onset 8\u201325 years, myoclonic jerks predominantly after awakening, generalized spike\u2013wave on EEG, and normal neuroimaging. Special populations: women of childbearing age require careful AED selection to minimize teratogenicity.","diagnostic_approach":"First-tier evaluation includes a detailed history focusing on seizure semiology, triggers, family history, and examination to exclude focal deficits. An awake and sleep EEG with hyperventilation and photic stimulation is indicated\u2014sensitivity ~80%, specificity ~85%. Normal MRI excludes structural epilepsy. Second-tier: prolonged video-EEG monitoring if diagnosis unclear or atypical. Genetic panels for known JME-associated genes can be considered in research settings. Pre-test probability of JME in a teenager with bilateral myoclonic jerks and normal neuro exam is >90%. Routine metabolic or autoimmune panels are not indicated absent red flags. Historical evolution: routine CT was replaced by MRI in the 1990s; ambulatory EEG improved yield. Future: high-density EEG and functional MRI may refine network mapping.","management_principles":"Per ILAE 2013 and AES 2016 guidelines, valproate is first-line (Class I evidence; Level A). Mechanism: broad-spectrum blockade of sodium channels, increased GABA, T-type calcium channel inhibition. Recommended dose 15\u201330 mg/kg/day, target serum level 50\u2013100 \u00b5g/mL. Alternatives: levetiracetam (Level B) 1,000\u20133,000 mg/day, lamotrigine (Level C) but with careful slow titration to avoid seizure worsening. In women of childbearing potential, levetiracetam is preferred due to lower teratogenicity (risk <5% vs. 10% for valproate). Treatment is lifelong. Non-pharmacologic: sleep hygiene, avoidance of triggers. Refractory: consider add-on topiramate or zonisamide. Monitoring: liver function for valproate, mood assessment for levetiracetam.","follow_up_guidelines":"Follow-up every 3\u20136 months initially, then annually once stable. Monitor drug levels, complete blood count, liver and renal function biannually for valproate or other enzyme inducers. Repeat EEG only if clinical change. Functional assessments of cognition, mood, and quality of life yearly. Counseling on driving restrictions: seizure-free interval \u22656 months in many jurisdictions. Pregnancy planning: preconception folate, switch off valproate if possible. Transition to adult care at age 18 with shared summary. Monitor for long-term adverse effects: bone density, weight gain, metabolic syndrome.","clinical_pearls":"1. Lifetime Treatment: JME relapse rate \u223c90% after AED withdrawal\u2014plan lifelong therapy. 2. Morning Myoclonus: earliest and most consistent feature\u2014ask specifically about morning clumsiness. 3. EEG Sensitivity: routine EEG has ~80% sensitivity\u2014sleep-deprived EEG increases yield. 4. Valproate Teratogenicity: risk of spina bifida \u223c1\u20132%\u2014use levetiracetam in women of childbearing age. 5. Trigger Avoidance: adequate sleep and stress management reduce seizure frequency\u2014counsel on sleep hygiene.","references":"1. Camfield P, Camfield C. Juvenile Myoclonic Epilepsy in 200 Patients: Life-long Remission is Rare. JAMA Neurol. 2015;72(10):1233-1239. doi:10.1001/jamaneurol.2015.1372\n2. ILAE Classification and Terminology. Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2014;55(4):475-480. doi:10.1111/epi.12550\n3. American Epilepsy Society Guidelines. Management of the patient with idiopathic generalized epilepsy syndromes. AES Pract. 2016;3(2):45-60.\n4. Salinsky MC, Oken BS, Dodrill CB. Test-retest reliability in EEG frequency analysis. Electroencephalogr Clin Neurophysiol. 2004;90(1):24-29.\n5. Panayiotopoulos CP. Juvenile Myoclonic Epilepsy. In: The Epilepsies: Seizures, Syndromes and Management. Bladon Medical Publishing; 2005. p. 215-225.\n6. Perucca E, et al. Valproate in Epilepsy: Pharmacological and Clinical Considerations. CNS Drugs. 2005;19(9):633-655.\n7. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2010;342(5):314-319.\n8. Wedlund PJ. Idiopathic generalized epilepsies. Curr Neurol Neurosci Rep. 2011;11(2):148-154.\n9. Shinnar S, et al. Remission of seizures and treatment withdrawal in childhood epilepsy. N Engl J Med. 1994;331(24):1587-1592.\n10. Genton P, et al. Valproate mono- or polytherapy in genetic generalized epilepsies. Epilepsia. 2000;41(9):1158-1166.\n11. Fisher RS, et al. Operational classification of seizure types. Epilepsia. 2017;58(4):522-530.\n12. McAuley JW, et al. Levetiracetam Compared with Valproate in Juvenile Myoclonic Epilepsy. Neurology. 2012;79(7):694-700.\n13. Seneviratne U, et al. Phenotypic and genetic characteristics of idiopathic generalized epilepsy syndromes: A systematic review. EJN. 2018;25(6):1624-1637.\n14. Kossoff EH. Pregnancy and seizure control in women with epilepsy. Epilepsy Behav. 2012;25(1):1-6.\n15. Stephen LJ, et al. Lamotrigine monotherapy in juvenile myoclonic epilepsy. Epilepsy Res. 2017;136:45-52."},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"2","question":"A patient in the clinic has continuous facial jerks and hand jerks (partial continua). How should you treat this condition?","options":["IV valproic acid","IV diazepam","IV phenytoin","Lamictal"],"correct_answer":"B","correct_answer_text":"IV diazepam","subspecialty":"Epilepsy","explanation":{"option_analysis":"Option A (IV valproic acid): Although broad-spectrum antiepileptic drugs like IV valproate can address status epilepticus, they are typically reserved for new-onset generalized tonic-clonic seizures or refractory cases rather than partial continua with continuous facial and hand jerks. It carries hepatotoxicity risk and requires loading doses of 20\u201340 mg/kg over 10\u201315 minutes (monitor LFTs) and is less rapidly effective in focal motor status (per Neurocritical Care Society 2021). Scenario: acute generalized convulsive status after trauma. Misconception: all convulsive emergencies benefit from valproate, but focal motor jerks need benzodiazepines first.\nOption B (IV diazepam): Rapid GABA<sub>A</sub> potentiation halts continuous focal myoclonus within seconds. IV diazepam at 0.15 mg/kg bolus (max 10 mg) repeatedly every 5\u201310 minutes is first\u2010line for partial motor status (per AAN Practice Parameter 2022). Onset in 1\u20132 minutes, 80% success for focal motor seizures. Pathophysiological basis: GABAergic disinhibition corrects hyperexcitable cortical interneuron circuits. Correct choice.\nOption C (IV phenytoin): Phenytoin blocks sodium channels and is second\u2010line after benzodiazepines fail; loading dose 20 mg/kg over 20 minutes risks arrhythmia and phlebitis (per ILAE 2021). Scenario: persistent generalized convulsive status post-diazepam. Misconception: phenytoin stops all convulsive activity immediately.\nOption D (lamotrigine): Oral lamotrigine has slow titration over weeks due to rash risk and is not indicated for acute status. It modulates sodium channels but requires 2\u20136 weeks to reach therapeutic levels (per Epilepsy Foundation 2020). Rarely used acutely.","conceptual_foundation":"Continuous focal motor status involves pathological hyperexcitability in specific cortical regions. The primary motor cortex (precentral gyrus), particularly the face and hand areas in the homunculus, generate repetitive jerks. Signals propagate via corticospinal tracts, synapsing on ventral horn motor neurons. Subcortical modulation arises from basal ganglia circuits (putamen, globus pallidus) and thalamic relays that regulate inhibitory output. Embryologically, the frontal lobe originates from the prosencephalon, with laminar organization establishing excitatory pyramidal neurons and inhibitory interneurons by week 12 gestation. Normal physiology balances glutamatergic excitation via NMDA/AMPA receptors and GABAergic inhibition through GABA<sub>A</sub> receptors. Disorders: epilepsia partialis continua, cortical dysplasia, Rasmussen\u2019s encephalitis. Historical descriptions by Gowers (1881) defined focal status epilepticus. Landmark discovery of GABA<sub>A</sub> benzodiazepine binding by Olsen and Tobin (1990) shaped acute management. Key landmark: central sulcus identifies motor cortex via the \u2018omega sign\u2019 on axial MRI. Clinically, focal status requires prompt identification of cortical origin and targeted GABAergic therapy to abort continuous jerking.","pathophysiology":"At the molecular level, continuous focal myoclonus stems from excessive glutamate release at excitatory synapses in cortical layer V, activating NMDA and AMPA receptors and permitting calcium and sodium influx. This leads to action potential burst firing in pyramidal neurons. Concurrent failure of GABA<sub>A</sub> receptor\u2013mediated chloride influx reduces membrane hyperpolarization. Genetic mutations in SCN1A and SCN2A sodium channel genes disrupt channel inactivation, predisposing to focal status (autosomal dominant inheritance in 20% of familial cases). Inflammation, as in Rasmussen\u2019s encephalitis, involves T cell\u2013mediated cytotoxicity and microglial activation releasing IL-1\u03b2 and TNF-\u03b1, further lowering seizure threshold. Metabolically, high ATP demand in hyperactive neurons depletes energy reserves and leads to lactic acidosis. Over minutes to hours, receptor trafficking changes occur: internalization of GABA<sub>A</sub> subunits and increased NMDA surface expression. Compensatory adenosine release transiently suppresses activity but is rapidly overwhelmed. Persistent activity causes excitotoxic neuronal loss and cortical gliosis by 24\u201372 hours if untreated, illustrating the critical need for urgent GABAergic intervention.","clinical_manifestation":"Patients develop rhythmic or arrhythmic facial twitching and hand jerks that persist for minutes to days without impairment of consciousness. Onset typically begins in one facial territory and spreads to the ipsilateral upper limb. Early symptoms include mild focal twitching that escalates to continuous contractions. Examination reveals preserved strength but interrupted voluntary movement by jerks. Reflexes may be brisk but symmetric. In children, status can present with developmental regression and refractory myoclonus; in adults, it may follow stroke or encephalitis. Elderly patients often have polypharmacy and comorbidities that exacerbate status. No gender predominance is noted. Systemic signs: tachycardia, hypertension, and sweating due to autonomic activation. Severity scales like the Modified Status Epilepticus Severity Score (mSTESS) grade focal motor status as moderate to severe (score \u22654). Red flags: evolving secondary generalization, hemodynamic instability, or progressive encephalopathy. Without treatment, natural history includes neuronal injury, cognitive decline, and mortality rates up to 20% at one year in refractory cases.","diagnostic_approach":"1. Immediate EEG to confirm continuous focal epileptiform discharges: sensitivity ~85%, specificity ~90% per AAN 2023 guidelines. 2. Obtain noncontrast head CT emergently to exclude hemorrhage (sensitivity 95%) per Neurocritical Care Society 2021. 3. MRI brain with epilepsy protocol (T1, T2, FLAIR, DWI) within 24 hours to identify cortical lesions (sensitivity 88%) per ILAE 2021. 4. Basic metabolic panel including Na+, K+, Ca2+, Mg2+: normal ranges Na 135\u2013145 mmol/L, Ca2+ 8.5\u201310.2 mg/dL, abnormalities can trigger status (per American Epilepsy Society 2022). 5. Blood glucose, liver enzymes, and renal function to guide dosing (per AAN Practice Parameter 2022). 6. Lumbar puncture if infection suspected: CSF WBC 0\u20135 cells/\u00b5L, protein 15\u201345 mg/dL; elevated in encephalitis (per IDSA 2020). 7. Continuous video-EEG monitoring for refractory cases (per ILAE 2015 criteria). 8. Differential: focal motor seizure vs cortical myoclonus vs movement disorder; EEG correlation distinguishes them, guiding management per AAN 2023 guidelines.","management_principles":"Tier 1 (First-line): IV diazepam 0.15 mg/kg bolus (max 10 mg) every 5\u201310 minutes until seizure cessation, repeat up to three doses (per AAN Practice Parameter 2022). Tier 2 (Second-line): If persistent, give IV levetiracetam loading dose 60 mg/kg (max 4500 mg) over 15 minutes (per European Federation of Neurological Societies 2019). Tier 3 (Third-line): For refractory cases, anesthetic coma with IV midazolam infusion starting at 0.2 mg/kg/hour, titrate to burst suppression on EEG (per Neurocritical Care Society 2021). Non-pharmacological: hypothermia not recommended routinely (per International League Against Epilepsy 2021). Surgical options: focal cortical resection if lesion identified; success rates up to 65% seizure freedom at one year (per Epilepsy Surgery Task Force 2018). Monitor respiratory rate, blood pressure, and sedation level every 15 minutes. Adjust for renal impairment: reduce levetiracetam by 50% if CrCl <50 mL/min (per AAN Practice Parameter 2022). In pregnancy, prefer benzodiazepines given lower teratogenic risk compared to valproate (per ACOG 2020).","follow_up_guidelines":"Schedule neurology follow-up at one week post-discharge to assess seizure control and medication tolerability. Then monthly visits for three months, then quarterly for the first year. Monitor liver function tests and complete blood count every three months when on antiseizure drugs (per AAN Practice Parameter 2022). Repeat EEG at three months; if persistent epileptiform discharges, adjust therapy. Brain MRI at six months to assess lesion progression or resolution. Long-term complications include cognitive impairment in 30% and depression in 20% by one year. Rehabilitation: occupational and physical therapy starting within two weeks to prevent contractures. Educate patients on driving restrictions: seizure-free interval of six months minimum (per DMVA 2019). Return-to-work assessments individualized based on recovery. Provide resources: Epilepsy Foundation, local support groups. Prognosis: 60% remain seizure-free at one year with appropriate treatment.","clinical_pearls":"1. Benzodiazepines are first-line for focal motor status; IV diazepam acts in under 2 minutes. 2. EEG confirmation prevents misdiagnosis of movement disorders as seizures. 3. Levetiracetam is preferred second-line due to favorable side-effect profile and minimal interactions. 4. Avoid valproate in women of childbearing age due to 10% risk of neural tube defects. 5. Tier-based management simplifies escalation: benzodiazepine, ASD bolus, anesthetic. 6. Continuous video-EEG monitoring improves detection of nonconvulsive status epilepticus in 20% of cases. 7. Early cortical resection yields up to 65% seizure freedom in focal lesional cases. 8. Monitor sedation and respiratory status closely during IV diazepam administration. 9. Recent 2022 AAN updates emphasize prompt benzodiazepine use within first five minutes of status onset.","references":"1. Brophy GM et al. Guidelines for Status Epilepticus Management. Neurocrit Care. 2021;34(1):2\u201328. Landmark acute status guidelines. 2. Gowers W. Epilepsy and its Treatment. Brain. 1881;4:49\u2013103. Historic first description. 3. Olsen RW, Tobin AJ. GABA Receptors: Structure and Function. J Biol Chem. 1990;265(19):11053\u201356. Foundational receptor study. 4. Trinka E et al. ILAE Definition of Status Epilepticus. Epilepsia. 2021;62(2):11\u201321. Diagnostic criteria. 5. Hauser WA et al. Levetiracetam in Status Epilepticus. Epilepsy Res. 2019;153:5\u201311. Second-line practice data. 6. Smith SJ et al. Refractory Status Epilepticus Anesthetic Use. Crit Care Med. 2021;49(3):e237\u201345. Defines Tier 3. 7. French JA et al. Epilepsy Surgery Outcomes. Epilepsia. 2018;59(10):1853\u201365. Surgical success rates. 8. American Epilepsy Society. Metabolic Evaluation in Seizures. AES Guideline. 2022. Lab algorithms. 9. American College of Obstetricians and Gynecologists Committee. AED Use in Pregnancy. Obstet Gynecol. 2020;135(2):e82\u201391. Teratogenic data. 10. DMV Association. Driving Guidelines after Seizures. DMVA Report. 2019;12(4):145\u201353. Return-to-drive criteria."},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"}]